Sepsis & infection

H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial

Crit Care MedPublished Secondary analysis of the SISPCT randomised trial

Primary result · 28-day mortality per one unit increase in log10 H3.1Result — go to the resultAdjusted hazard ratio 1.48 95% CI 1.07–2.04

Authors' conclusion

Elevated levels of H3.1 nucleosomes at admission are associated with mortality and AKI requiring RRT.

Study context

Population
Patients with sepsis or septic shock from 33 ICUs in Germany, 2009–2013927 with complete renal replacement therapy (RRT) data
Participants
971 patients
Comparison
Admission plasma H3.1 nucleosome levels as predictor of RRT and 28-day mortality
  • Sepsisn = 443reference
  • Septic shockn = 520
Primary endpoint
28-day mortality and time to commencement of RRT
Follow-up
28 days
Methodological detailsprospectively collected samples, multicentre, multivariable Cox regression
  • Prospectively collected samples
  • Multicentre
  • Multivariable Cox regression

Primary result

As reported in the abstract

28-day mortality per one unit increase in log10 H3.1

Adjusted hazard ratio

1.48

95% CI 1.07–2.04

P = 0.02

log10 H3.1 (per unit increase)
aHR 1.48 (95% CI 1.07–2.04); P = 0.02

Per unit increase, as printed

Further findings

28-day RRT (acute kidney injury (AKI) requiring RRT)

Adjusted HR (95% CI)P value
One log10 increase of H3.1Risk of 28-day RRT increased by 80%1.8 (1.34–2.40)P < 0.001

Admission plasma H3.1 levels, septic shock vs sepsis

P < 0.001

Plasma H3.1 in stage 3 AKI requiring RRT (subgroup), septic shock vs sepsis

P = 0.01

  • 28-day RRT (AKI requiring RRT): multivariable Cox regression controlling for maximum lactate, procalcitonin, and C-reactive protein levels

Original publication

H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial. Crit Care Med. Published 3 August 2026. doi:10.1097/ccm.0000000000007270

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.